Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole

被引:47
作者
Balashov, SV
Gardiner, R
Park, S
Perlin, DS
机构
[1] Int Ctr Publ Hlth, Publ Hlth Res Inst, Newark, NJ 07103 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA
关键词
D O I
10.1128/JCM.43.1.214-222.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Aspergillus fumigatus is an important cause of life-threatening invasive fungal disease in patients with compromised immune systems. Resistance to itraconazole in A. fumigatus is closely linked to amino acid substitutions in Cyp51A that replace Gly54. In an effort to develop a new class of molecular diagnostic assay that can rapidly assess drug resistance, a multiplexed assay was established. This assay uses molecular beacons corresponding to the wild-type cyp51A gene and seven mutant alleles encoding either Arg54, Lys54, Val54, Trp54, or Glu54. Molecular beacon structure design and real-time PCR conditions were optimized to increase the assay specificity. The multiplex assay was applied to the analysis of chromosomal DNA samples from a collection of 48 A. fumigatus clinical and laboratory-derived isolates, most with reduced susceptibility to itraconazole. The cyp51A allelic identities for codon 54 were established for all of the strains tested, and mutations altering Gly54 in 23 strains were revealed. These mutations included G(54)W (n = 1), G(54)E (n = 12), G(54)K (n = 3), G(54)R (n = 3), and G(54)V (n = 4). Molecular beacon assay results were confirmed by DNA sequencing. Multiplex real-time PCR with molecular beacons is a powerful technique for allele differentiation and analysis of resistance mutations that is dynamic and suitable for rapid high-throughput assessment of drug resistance.
引用
收藏
页码:214 / 222
页数:9
相关论文
共 48 条
[1]   Thermodynamic basis of the enhanced specificity of structured DNA probes [J].
Bonnet, G ;
Tyagi, S ;
Libchaber, A ;
Kramer, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (11) :6171-6176
[2]   Utility of random amplified polymorphic DNA PCR and TaqMan automated detection in molecular identification of Aspergillus fumigatus [J].
Brandt, ME ;
Padhye, AA ;
Mayer, LW ;
Holloway, BP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (07) :2057-2062
[3]   Acquired itraconazole resistance in Aspergillus fumigatus [J].
Dannaoui, E ;
Borel, E ;
Monier, MF ;
Piens, MA ;
Picot, S ;
Persat, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :333-340
[4]   Echinocandin antifungal drugs [J].
Denning, DW .
LANCET, 2003, 362 (9390) :1142-1151
[5]   TREATMENT OF INVASIVE ASPERGILLOSIS WITH ITRACONAZOLE [J].
DENNING, DW ;
TUCKER, RM ;
HANSON, LH ;
STEVENS, DA .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) :791-800
[6]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[7]   A point mutation in the 14α-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus [J].
Diaz-Guerra, TM ;
Mellado, E ;
Cuenca-Estrella, M ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :1120-1124
[8]  
Feldmesser Marta, 2003, Am J Respir Med, V2, P371
[9]   New antifungal agents [J].
Gupta, AK ;
Tomas, E .
DERMATOLOGIC CLINICS, 2003, 21 (03) :565-+
[10]   Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients [J].
Herbrecht, R ;
Letscher-Bru, V ;
Oprea, C ;
Lioure, B ;
Waller, J ;
Campos, F ;
Villard, O ;
Liu, KL ;
Natarajan-Amé, S ;
Lutz, P ;
Dufour, P ;
Bergerat, JP ;
Candolfi, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1898-1906